CLAIMS

1. An isolated polypeptide, said polypeptide comprising a material selected from the group consisting of :

a) an amino acid sequence set out in SEQ ID NO: 1;

b) a derivative of an amino acid sequence set out in SEQ ID NO: 1, wherein said derivative is an amino acid sequence set out in SEQ ID NO: 1 having one or more amino acid substitutions, deletions or insertions; and

c) a fragment of an amino acid sequence of a) or b), said fragment comprising at least ten amino acids.

2. The isolated polypeptide of claim 1, wherein said derivative is an amino acid sequence set out in SEQ ID NO: 1 having one or more amino acid substitutions, deletions or insertions and said derivative is at least 75% identical to the amino acid sequence set out in SEQ ID NO: 1.

3. The isolated polypeptide of claim 1, wherein said isolated polypeptide is operably linked to a second amino acid sequence to generate a fusion polypeptide.

4. An isolated or recombinant nucleic acid molecule, said isolated or recombinant nucleic acid molecule comprising:

a) a nucleic acid sequence set out in SEQ ID NO:2 or an RNA transcribed therefrom;

b) a nucleic acid sequence encoding a derivative of an amino acid sequence set out in SEQ ID NO: 1, wherein said derivative comprises an amino acid sequence set out in SEQ ID NO: 1 having one or more substitutions, deletions or insertions;

c) a nucleic acid sequence encoding a fragment of a amino acid sequence set out in SEQ ID NO:1;

d) a nucleic acid sequence complementary to a nucleic acid sequence of a) or b);

e) a nucleic acid sequence encoding a polypeptide, wherein said polypeptide is identical to an amino acid sequence of a), b) or c); or

f) a nucleic acid sequence having substantial identity to a nucleic acid sequence of a), b), c) and d).

5. A vector comprising at least one nucleic acid molecule of claim 4.

6. A host cell comprising the vector of claim 5.

7. A method for screening and/or diagnosing breast cancer or monitoring and/or assessing breast cancer treatment in a subject, said method comprising detecting and/or quantifying an amount of a polypeptide of claim 1 or a nucleic acid molecule of claim 4 in a biological sample of said subject.

8. An antibody capable of binding specifically to a polypeptide of claim 1.

9. The antibody of claim 8, wherein the antibody is a monoclonal antibody, a bispecific antibody, a chimeric antibody, or a humanised antibody.

10. The antibody of claim 9, wherein the antibody is conjugated to a therapeutic moiety, said therapeutic moiety selected from the group consisting of a second antibody or a fragment or derivative thereof, a cytotoxic agent and a cytokine.

11. A method of screening for agents capable of interacting with at least one polypeptide of claim 1, said method comprising:

(a) contacting a polypeptide of claim 1 with a candidate agent; and

(b) determining if the candidate agent interacts with said polypeptide, wherein determination of an interaction of a candidate agent with said polypeptide identifies a candidate agent capable of interacting with at least one polypeptide of claim 1.

12. The method according to claim 11, wherein the determination of an interaction of a candidate agent with the polypeptide comprises quantitatively detecting binding of the candidate agent to said polypeptide.

13. A method of screening for agents capable of modulating

i) expression and/or activity of a polypeptide of claim 1, or

ii) expression of a nucleic acid molecule of claim 4,

said method comprising:

a) comparing the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule in the presence of a candidate agent with the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule in the absence of the candidate agent or in the presence of a control agent; and

b) determining whether the presence of the candidate agent modulates the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule.

14. The method of claim 13 wherein the expression and/or activity level of said polypeptide or the expression level of said nucleic acid molecule is compared to a predetermined reference range.

15. The method of claim 13 wherein step (b) further comprises selecting an agent capable of modulating the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule and testing said agent for use as a therapeutic or prophylactic anti-breast cancer agent.

16. An agent identified by the method of claim 13, wherein said agent alters the expression and/or activity of said polypeptide or the expression of said nucleic acid molecule.

17. A medicament for use in prophylaxis and/or treatment of cancer, said medicament comprising a material selected from the group consisting of

: a) at least one polypeptide of claim 1;

b) at least one nucleic acid molecule of claim 4f);

c) at least one antibody capable of binding specifically to said at least one polypeptide; and

d) at least one agent capable of modulating the expression and/or activity of said at least one polypeptide or the expression of said nucleic acid molecule.

18. The medicament of claim 17, wherein said medicament is used for prophylaxis and/or treatment of breast cancer.

19. A pharmaceutical composition comprising a material selected from the group consisting of:

a) at least one polypeptide of claim 1;

b) at least one nucleic acid molecule of claim 4f);

c) at least one antibody capable of binding specifically to said at least one polypeptide;

d) at least one agent capable of modulating the expression and/or activity of said at least one polypeptide or the expression of said nucleic acid molecule and

e) one or more of the above together with at least one of pharmaceutically acceptable excipients, adjuvants, carriers and diluents.

20. A method for prophylaxis and/or treatment of breast cancer in a subject, said method comprising administering to said subject a therapeutically effective amount of:

a) at least one polypeptide of claim 1;

b) at least one nucleic acid molecule of claim 4f);

d) at least one antibody capable of binding specifically to said at least one polypeptide; and

e) at least one agent capable of modulating the expression and/or activity of said at least one polypeptide or the expression of said nucleic acid molecule.

21. The pharmaceutical composition of claim 19 wherein the pharmaceutical composition is a vaccine.